Business Context and Reporting Period
This Form 8-K is a current report filed by Halozyme Therapeutics, Inc. on December 9, 2025, regarding an event that occurred on December 4, 2025. The filing discloses a new compensatory arrangement for the Company's Chief Executive Officer, Dr. Helen Torley.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, or debt metrics. The only financial figure disclosed is the grant date fair value of the new equity award.
- Grant Date Fair Value: $10 million (for the target number of shares).
- Valuation Method: Monte Carlo valuation model in accordance with U.S. GAAP.
Material Changes
The material change reported is the approval of a one-time performance-based restricted stock unit (PSU) grant for Dr. Helen Torley under the Company's 2021 Stock Plan. This grant is designed to incentivize stock price performance and retain executive leadership.
Guidance, Outlook, and Management Commentary
Management intends for this grant to retain Dr. Torley and incentivize her to drive growth and profitability during the Company's next stage of growth. The award structure ties vesting to specific stock price milestones over a four-year performance period:
- 0% Vesting: If the average stock price never reaches $115.00.
- 50% of Target: If the average stock price equals or exceeds $115.00.
- 100% of Target: If the average stock price equals or exceeds $130.00.
- 150% of Target: If the average stock price equals or exceeds $145.00.
- 200% of Target: If the average stock price equals or exceeds $170.00.
Vesting Conditions: Shares eligible to vest based on price targets will only vest if Dr. Torley remains employed through the fourth anniversary of the grant date. Voluntary resignation or retirement prior to this date results in forfeiture of all performance-based vested shares. The average price is calculated using the average of closing prices over 20 consecutive trading days.
Investor Verification Checklist
- Verify the exact number of shares in the "target" grant, as the filing only discloses the $10 million fair value.
- Review the full award agreement (to be filed as an exhibit to the 2025 Form 10-K) for specific exceptions to the employment requirement.
- Monitor the Company's stock price performance relative to the $115.00 threshold to determine if any vesting is possible.
- Confirm the impact of this grant on future dilution and compensation expense in upcoming quarterly reports.